Curated News
By: NewsRamp Editorial Staff
April 29, 2025
Annovis Bio Names Hui Liu Director of Biostatistics for Phase 3 Alzheimer’s Trial
TLDR
- Hui Liu's appointment enhances Annovis Bio's Alzheimer's Phase 3 trial, giving a strategic advantage in developing transformative therapies.
- Hui Liu's 19 years of experience in clinical trial design and data analysis will strengthen Annovis Bio's scientific integrity in neurodegenerative therapy development.
- Annovis Bio's focus on neurodegenerative diseases like Alzheimer's and Parkinson's aims to improve patients' quality of life by restoring brain function.
- Annovis Bio's appointment of Hui Liu brings expertise in clinical trial design, offering insights into developing therapies for neurodegenerative disorders.
Impact - Why it Matters
This news highlights the crucial role of Hui Liu in advancing Annovis Bio's mission to address neurodegeneration, potentially leading to groundbreaking treatments for patients suffering from Alzheimer's and Parkinson's diseases.
Summary
Annovis Bio (NYSE: ANVS) appoints Hui Liu as Director of Biostatistics to enhance its Phase 3 Alzheimer’s disease trial. Liu's expertise will strengthen data integrity and regulatory strategies for the development of transformative neurodegenerative therapies.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Annovis Bio Names Hui Liu Director of Biostatistics for Phase 3 Alzheimer’s Trial
